Late-Onset Fulminant Myocarditis With Immune Checkpoint Inhibitor Nivolumab-Reference-Cited by-同舟云学术

Late-Onset Fulminant Myocarditis With Immune Checkpoint Inhibitor Nivolumab

Published:2018-06 Issue:6 Volume:34 Page:812.e1-812.e3
ISSN:0828-282X
Container-title:Canadian Journal of Cardiology
language:en
Short-container-title:Canadian Journal of Cardiology

Author:

Yamaguchi Shogo,Morimoto Ryota,Okumura Takahiro^ORCID,Yamashita Yuta,Haga Tomoaki,Kuwayama Tasuku,Yokoi Tsuyoshi,Hiraiwa Hiroaki,Kondo Toru,Sugiura Yuki,Watanabe Naoki,Kano Naoaki,Kohno Kei,Fukaya Kenji,Sawamura Akinori^ORCID,Yokota Kenji,Ishii Hideki,Nakaguro Masato,Akiyama Masashi,Murohara Toyoaki

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference5 articles.

1. Cardiac toxicity of immune checkpoint inhibitors: cardio-oncology meets immunology;Varricchi;Circulation,2017

2. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies;Naidoo;Ann Oncol,2015

3. PD-1 protects against inflammation and myocyte damage in T cell-mediated myocarditis;Tarrio;J Immunol,2012

4. Endothelial programmed death-1 ligand 1 (PD-L1) regulates CD8+ T-cell mediated injury in the heart;Grabie;Circulation,2007

5. Fulminant myocarditis with combination immune checkpoint blockade;Johnson;N Engl J Med,2016

Cited by 61 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Steroid-Refractory Myocarditis Induced by Immune Checkpoint Inhibitor Responded to Infliximab: Report of Two Cases and Literature Review;Cardiovascular Toxicology;2024-09-10

2. Case report: Regression after low-dose glucocorticoid therapy in a case of acute immune myocarditis induced by anti-PD-1 therapy for NSCLC;Frontiers in Oncology;2024-05-24

3. Immune checkpoint inhibitors break whose heart? Perspectives from cardio-immuno-oncology;Genes & Diseases;2024-03

4. Immune checkpoint inhibitor myocarditis in thymic epithelial tumors: a case report and literature review;Translational Cancer Research;2024-02

5. Clinical characteristics, diagnosis and management of nivolumab-induced myocarditis;Investigational New Drugs;2024-01-23